SoftOx Solutions

Equities

SOFTX

NO0010811961

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-07-05 EDT			5-day change	1st Jan Change
0.0836 ^NOK	-3.69%		-45.36%	-97.42%

07-02	Softox Solutions as Announces CFO Changes	CI
07-02	Softox Solutions as Announces New Board and Leadership	CI

SoftOx : Financial calendar 2024

June 19, 2024 at 08:58 am

Financial calendar 2024

19 Jun 2024 11:48 CEST

Issuer

SoftOx Solutions AS

Financial calendar 2024

FINANCIAL YEAR 2023
20.03.2024 Quarterly Report - Q4
31.05.2024 Annual Report 2023
28.06.2024 Annual General Meeting

FINANCIAL YEAR 2024
25.09.2024 Half Year Report
18.06.2025 Annual Report
25.06.2025 Annual General Meeting

28.06.2024 Quarterly Report - Q1
27.11.2024 Quarterly Report - Q3
05.03.2025 Quarterly Report - Q4

More information:
Access the news on Oslo Bors NewsWeb site

Source

SoftOx Solutions AS

Provider

Oslo Børs Newspoint

Company Name

SOFTOX SOLUTIONS

ISIN

NO0010811961

Symbol

SOFTX

Market

Euronext Growth

Attachments

Original Link
Permalink

Disclaimer

SoftOx Solutions AS published this content on 19 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 June 2024 12:57:47 UTC.

Latest news about SoftOx Solutions

Softox Solutions as Announces CFO Changes	07-02	CI
Softox Solutions as Announces New Board and Leadership	07-02	CI
SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2024	06-28	CI
Transcript : SoftOx Solutions AS - Special Call	04-18
SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-19	CI
SoftOx Solutions Seeks Extension of NOK40 Million Convertible Loan; Shares Jump	01-16	MT
SoftOx Solutions AS announced that it expects to receive NOK 40 million in funding	01-10	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10-31	CI
SoftOx Solutions AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-26	CI
SoftOx Solutions Faces Penalty from Oslo Børs	23-09-18	MT
SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-21	CI
SoftOx Solutions AS announced that it has received NOK 15 million in funding	23-06-08	CI
Oslo Børs Places Seven Issuers in Penalty Bench over Public Disclosure Rule Violations	23-06-02	MT
SoftOx Solutions Launches Temporary Layoffs Amid Restructuring; Shares Down 29%	23-03-27	MT
Softox Solutions AS Announces Resignation of Kari Myren from the Board	23-03-24	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-15	CI
Softox Solutions Announces Signing of the Final Grant Agreement for the Counteract Consortium	23-01-09	CI
SoftOx Solutions Appoints Interim CEO, New CFO	22-12-20	MT
SoftOx Solutions AS Appoints Christian Harstad as the Interim Chief Executive Officer	22-12-19	CI
SoftOx Solutions AS Announces Chief Financial Officer Changes	22-12-19	CI
Softox Solutions AS Announces Final Report Reaffirms Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	22-12-14	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-26	CI
Softox Solutions Receives Swedish Approval For Disinfect Product	22-10-19	MT
Softox Solutions AS Announces Approval from the Swedish Chemicals Agency on Disinfection Products	22-10-18	CI

Chart SoftOx Solutions

Duration

Period

More charts

Company Profile

SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOxâs product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.

Sector

Biotechnology & Medical Research

Calendar

2024-09-03 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SOFTOX SOLUTIONS	-97.42%	4.09M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.56B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs